Top

Published in:

01-10-2006 | Original Article

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

Authors: Wacharee Seeherunvong, Obioma Nwobi, Carolyn L. Abitbol, Jayanthi Chandar, José Strauss, Gastón Zilleruelo

Published in: Pediatric Nephrology | Issue 10/2006

Abstract

Secondary hyperparathyroidism (SHPT) remains a treatment dilemma in pediatric dialysis patients. Recent experience with paricalcitol (P), a vitamin D analogue, in adults with SHPT has shown equal efficacy and improved survival compared to traditional treatment with calcitriol (C). We present our experience with (C) compared to (P) treatment in our pediatric dialysis patients with SHPT. Twenty-one patients (mean age 11.5±5 years) with SHPT (intact parathyroid hormone (iPTH) averaging 1,228±496 pg/ml) were studied. Seventeen received (C) followed by (P); while an additional four were treated with either (C=1) or (P=3) alone. After 26±8 weeks, average percent (%) decrease in iPTH was similar with (C) and (P) (−60.4±34% versus −65.4±28%, respectively; p=0.6). In the (P) group, the effective dose in children was greater than in adult trials based on kilogram weight. Episodes of hypercalcemia between the treatment groups were not different. However, episodes of elevated calcium × phosphorus product (Ca×P)≥70 mg²/dl² occurred more frequently in the (C) group (odds ratio=1.5; p=0.01). Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients.

National Kidney Foundation (2005) K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1–S103

Salusky I (2005) Are new Vitamin D analogues in renal disease superior to calcitriol? Pediatr Nephrol 20:393–398CrossRef

Sanchez CP (2003) Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Pediatr Drugs 5:763–776CrossRef

Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatopolsky E, Coburn JW (1987) “High-dose” calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32:89–95CrossRef

Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W (1993) Renal bone disease in pediatric and young adult patients on hemodialysis in a children’s hospital. J Am Soc Nephrol 3:1938–1946PubMed

Slatopolsky E, Brown A, Dusso A (1999) Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73:S14–S19CrossRef

Llach F, Velasquez Forero F (2001) Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 38:S20–S33CrossRef

Greenbaum L, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB (2005) Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 20:622–630CrossRef

Cano F, Delucchi A, Wolff E, Rodriguez E, Fuentes A (1995) Calcitriol oral pulse therapy in children with renal osteodystrophy. Pediatr Nephrol 9:606–608CrossRef

10.

Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274–279CrossRef

11.

Quarles LD, Yohay DA, Carroll BA, Spritzer CF, Minda SA, Bartholomay D, Lobaugh BA (1994) Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710–1721CrossRef

12.

Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GB, Salusky IR (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160–1166CrossRef

13.

Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-nor-1-α-25-dihydroxyvitamin D₂ (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427–1432PubMed

14.

Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56:315–323PubMed

15.

Melnick JZ, Kommala D, Mattingly S, Amdahl M, Greenbaum WL (2004) Paricalcitol and calcitriol in treating SHPT children: a comparison of 2 studies. St. Louis, MO, GPRD, Abbott Laboratories, Abbott Park, IL; Pediatrics Medical College of Wisconsin, Milwaukee, WI [Abstract]. J Am Soc Nephrol SU-PO939

16.

Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38(5Suppl 5):S45–S50CrossRef

17.

Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D₂. Am J Kidney Dis 32:S48–S54CrossRef

18.

Sprague SM, Llach F, Amdahl M, Tacetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483–1490CrossRef

19.

Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E (2002) Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283–1288CrossRef

20.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456CrossRef

21.

Korkor AB (1987) Reduced binding of 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316:1573–1577CrossRef

22.

Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436–1443CrossRef

23.

Carling T, Rastad J, Szabo E, Westin G, Akerstrom G (2000) Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 85:2000–2003PubMed

24.

Martin KJ, Gonzalez E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F (2001) Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 38:S57–S63CrossRef

25.

Kuizon D, Goodman W, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205–211CrossRef

26.

Sanchez CP, He YZ (2005) Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism. J Am Soc Nephrol 16:929–938CrossRef

27.

Paczyk-Tomaszewska M, Ziókowska H, Debinski A, Sieniawska M (2000) Vitamin D metabolite requirements in dialysed children receiving recombinant human growth hormone. Nephrol Dial Transplant 15:375–378CrossRef

28.

US Government (2006) VISN 21 Criteria for non-formulary use of paricalcitol. US Department of Veterans Affairs, USA

29.

Dobrez D, Mathes A, Amdahl M, Marx S, Melnick J, Sprague S (2004) Paricalcitol-treated patients experience improved hospitalization outcomes compared to calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174–1181CrossRef

Title: Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients
Authors: Wacharee Seeherunvong
Obioma Nwobi
Carolyn L. Abitbol
Jayanthi Chandar
José Strauss
Gastón Zilleruelo
Publication date: 01-10-2006
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 10/2006
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-006-0204-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2006

Mechanisms of development and progression of cyanotic nephropathy

PRCC-TFE3 Renal cell carcinoma in a boy with a history of contralateral mesoblastic nephroma

Acute effects of gentamicin on glomerular and tubular functions in preterm neonates

Different pathomechanisms of essential and obesity-associated hypertension in adolescents

Renal cystic diseases: diverse phenotypes converge on the cilium/centrosome complex

Living unrelated—commercial—kidney transplantation: when there is no chance to survive